Results 51 to 60 of about 10,090 (144)

Real‐world use of second‐generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS‐CO3‐AquiVIH‐NA cohort

HIV Medicine, EarlyView.
Abstract Objectives To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods People living with HIV from the prospective ANRS‐CO3‐
O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, A. Riché, Y. Gérard, G. Barrière, S. Reigadas, M.‐A. Vandenhende, F. Bonnet   +15 more
wiley   +1 more source

Prevalence of Sleep Apnea and Sleepiness in Adults With and Without HIV in Mwanza, Tanzania: Baseline Results From an Ongoing Cohort Study

Journal of Sleep Research, EarlyView.
ABSTRACT We conducted a cross‐sectional analysis of the baseline survey of participants aged > 30 years enrolled in the Mwanza HIV&CVD Cohort in Tanzania. Our primary objective was to examine the association between HIV status and sleep apnea (SA).
Godfrey A. Kisigo, Benson Issarow, Salama Fadhil, Grace Ruselu, Ponsiano Fabian, Ayubu Garbindi, Robert N. Peck, Kathy Baisley, Saidi Kapiga, Ana C. Krieger   +9 more
wiley   +1 more source

Cytopenias With HIV in the Era of Highly Active Antiretroviral Therapy: Are We Winning the Battle?

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aim Cytopenias remain among the most frequent hematologic complications of HIV infection, affecting treatment outcomes and quality of life. The introduction of highly active antiretroviral therapy has markedly reduced their incidence by restoring immune function and suppressing viral replication.
Emmanuel Ifeanyi Obeagu
wiley   +1 more source

An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form

Future Journal of Pharmaceutical Sciences, 2020
Background A Simple, sensitive, and specific stability indicating reverse phase HPLC method was developed for simultaneous estimation of Lamivudine and Dolutegravir in bulk and tablet dosage form.
Ramreddy Godela, Sowjanya G
doaj   +1 more source

Systematic De-escalation of Successful Triple Antiretroviral Therapy to Dual Therapy with Dolutegravir plus Emtricitabine or Lamivudine in Swiss HIV-positive Persons

EClinicalMedicine, 2018
Background: Studies increasingly suggest that the efficacy of certain dual antiretroviral therapy (ART) combinations is equal to triple ART. Increasing concerns among HIV-positive patients and physicians in Switzerland include ART cost and long-term ART ...
Natascha D. Diaco, Claudio Strickler, Stéphanie Giezendanner, Sebastian A. Wirz, Philip E. Tarr   +4 more
doaj   +1 more source

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions

Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 314-317, February 2026.
Physiology Based Pharmacokinetic (PBPK) modeling is an established essential tool for predicting and/or analyzing drug–drug interactions (DDI). Uncertainty and variability associated with in vitro determined DDI‐related parameters have often been considered a limitation for predicting PBPK‐DDIs.
Kunal S. Taskar, Pradeep Sharma, Karen Rowland Yeo   +2 more
wiley   +1 more source

Spectrophotometric quantification of dolutegravir based on redox reaction with Fe3+/1,10-phenanthroline

Future Journal of Pharmaceutical Sciences, 2020
Background A simple and sensitive spectrophotometric method was developed for the quantitative measurement of dolutegravir in pure form and pharmaceutical formulation.
Swathi Naraparaju, Durai Ananda Kumar Thirumoorthy, Sunitha Gurrala, Asra Jabeen, Pani Kumar D. Anumolu   +4 more
doaj   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Inflammatory Biomarkers Decay After First‐Line Antiretroviral Therapy Initiation With Dolutegravir/Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide in Persons With HIV: A Substudy of a Randomized Clinical Trial

Health Science Reports, Volume 9, Issue 3, March 2026.
Analuz Fernandez, Sofía Scevola, Raul Rigo Bonin, Maria Saumoy, Arkaitz Imaz, Daniel Podzamczer, Juan Tiraboschi   +6 more
wiley   +1 more source

Dolutegravir [PDF]

Reactions Weekly, 2020
  +4 more sources